The drug maker remains a robust—and inexpensive—growth story. It isn’t being given its due by Wall Street. Source link"Vertex Looks to Cash In On Its Rich Drug Pipeline"
Holiday sales disappointments and poor outlooks could weigh on specialty retail and department store stocks in Q1. Source link"Amazon, Burlington Will Have Heavy Holiday Presence"